title: Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results.
abstract: OBJECTIVE
  To compare the efficacy of esomeprazole, 20 mg once daily, vs. lansoprazole, 15 mg once daily, for the maintenance treatment of patients with healed reflux oesophagitis.
  
  
  METHODS
  During the initial open healing phase, 1391 patients with endoscopically verified reflux oesophagitis and a history of heartburn, with or without acid regurgitation, received esomeprazole 40 mg for 4-8 weeks. Patients who were healed (identified by endoscopy at 4 or 8 weeks) and symptom free were then randomized to receive 6 months of treatment with esomeprazole, 20 mg once daily, or lansoprazole, 15 mg once daily.
  
  
  RESULTS
  Esomeprazole, 20 mg once daily, maintained a significantly higher proportion of patients in remission than lansoprazole, 15 mg once daily, over 6 months [83% (95% CI, 80-86%) of esomeprazole recipients compared with 74% (95% CI, 70-78%) of lansoprazole recipients; P < 0.0001; life table estimates]. When data were analysed according to baseline Los Angeles grade classification, esomeprazole, 20 mg once daily, achieved consistently higher remission rates across all grades of disease severity, whereas the efficacy of lansoprazole decreased to a greater extent with increasing severity of reflux oesophagitis.
  
  
  CONCLUSIONS
  Esomeprazole, 20 mg once daily, is more effective than lansoprazole, 15 mg once daily, in maintaining remission in patients with healed reflux oesophagitis.
authors.affiliation: Department of Gastroenterology, Odense University Hospital, Denmark. karsten.lauritsen@ouh.fyns-amt.dk
authors.forename: K
authors.initials: K
authors.lastname: Lauritsen
authors.forename: J
authors.initials: J
authors.lastname: Devière
authors.forename: M-A
authors.initials: MA
authors.lastname: Bigard
authors.forename: E
authors.initials: E
authors.lastname: Bayerdörffer
authors.forename: G
authors.initials: G
authors.lastname: Mózsik
authors.forename: F
authors.initials: F
authors.lastname: Murray
authors.forename: S
authors.initials: S
authors.lastname: Kristjánsdóttir
authors.forename: V
authors.initials: V
authors.lastname: Savarino
authors.forename: K
authors.initials: K
authors.lastname: Vetvik
authors.forename: D
authors.initials: D
authors.lastname: De Freitas
authors.forename: V
authors.initials: V
authors.lastname: Orive
authors.forename: L
authors.initials: L
authors.lastname: Rodrigo
authors.forename: M
authors.initials: M
authors.lastname: Fried
authors.forename: J
authors.initials: J
authors.lastname: Morris
authors.forename: H
authors.initials: H
authors.lastname: Schneider
authors.forename: S
authors.initials: S
authors.lastname: Eklund
authors.forename: A
authors.initials: A
authors.lastname: Larkö
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D064098:Esomeprazole / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives; D004941:Esophagitis / Q000188:drug therapy*; D005260:Female; D005764:Gastroesophageal Reflux; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D054328:Proton Pump Inhibitors; D012008:Recurrence; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D064098:Esomeprazole